Indirect comparisons of oral fingolimod versus natalizumab and cladribine for the treatment of relapsing-remitting multiple sclerosis based on data from FREEDOMS, AFFIRM and CLARITY

被引：0
|
作者：
Nixon, R.
Eckert, B.
Cutter, G.
Mercier, F.
Francis, G.
Kappos, L.
机构：
[1] Novartis Pharma AG, Basel, Switzerland
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Novartis Inst Biomed Res Inc, Cambridge, MA USA
[5] Univ Basel Hosp, CH-4031 Basel, Switzerland
来源：
JOURNAL OF NEUROLOGY | 2012年 / 259卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S68 / S68
页数：1
相关论文
共 50 条
  • [1] Indirect Comparisons of Oral Fingolimod Versus Natalizumab on Measures of Disease Freedom Based on Results from FREEDOMS and AFFIRM
    Nixon, Richard
    Bergvall, Niklas
    Sfikas, Nikolaos
    Chin, Peter
    Tomic, Davorka
    Cutter, Gary
    Kappos, Ludwig
    NEUROLOGY, 2013, 80
  • [2] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Izquierdo, Guillermo
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Girard, Marc
    Duquette, Pierre
    Yamout, Bassem I.
    Khoury, Samia
    Van Pesch, Vincent
    Macdonell, Richard
    Sa, Maria Jose
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Al-Asmi, Abdullah
    Robertson, Neil
    Coles, Alasdair
    Brown, J. William L.
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 629 - 631
  • [3] Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
    Kalincik, Tomas
    Horakova, Dana
    Spelman, Tim
    Jokubaitis, Vilija
    Trojano, Maria
    Lugaresi, Alessandra
    Izquierdo, Guillermo
    Rozsa, Csilla
    Grammond, Pierre
    Alroughani, Raed
    Duquette, Pierre
    Girard, Marc
    Pucci, Eugenio
    Lechner-Scott, Jeannette
    Slee, Mark
    Fernandez-Bolanos, Ricardo
    Grand'Maison, Francois
    Hupperts, Raymond
    Verheul, Freek
    Hodgkinson, Suzanne
    Oreja-Guevara, Celia
    Spitaleri, Daniele
    Barnett, Michael
    Terzi, Murat
    Bergamaschi, Roberto
    McCombe, Pamela
    Sanchez-Menoyo, Jose
    Simo, Magdolna
    Csepany, Tunde
    Rum, Gabor
    Boz, Cavit
    Havrdova, Eva
    Butzkueven, Helmut
    ANNALS OF NEUROLOGY, 2015, 77 (03) : 425 - 435
  • [4] Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis
    Roos, Izanne
    Sharmin, Sifat
    Malpas, Charles
    Ozakbas, Serkan
    Lechner-Scott, Jeannette
    Hodgkinson, Suzanne
    Alroughani, Raed
    Eichau Madueno, Sara
    Boz, Cavit
    van der Walt, Anneke
    Butzkueven, Helmut
    Buzzard, Katherine
    Skibina, Olga
    Foschi, Matteo
    Grand'Maison, Francois
    John, Nevin
    Grammond, Pierre
    Terzi, Murat
    Prevost, Julie
    Barnett, Michael
    Laureys, Guy
    Van Hijfte, Liesbeth
    Luis Sanchez-Menoyo, Jose
    Blanco, Yolanda
    Oh, Jiwon
    Mccombe, Pamela
    Ramo Tello, Cristina
    Soysal, Aysun
    Prat, Alexandre
    Duquette, Pierre
    Yamout, Bassem, I
    Khoury, Samia
    van Pesch, Vincent
    Macdonell, Richard
    Jose Sa, Maria
    Slee, Mark
    Kuhle, Jens
    Maimone, Davide
    Spitaleri, Daniele L. A.
    Willekens, Barbara
    Asmi, Abdallah Al
    Tallantyre, Emma
    Robertson, Neil P.
    Coles, Alasdair
    Brown, J. William
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (09) : 1163 - 1175
  • [5] ORAL FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Vosiliou, S.
    DRUGS OF TODAY, 2010, 46 (05) : 315 - 325
  • [6] ECONOMIC EVALUATION OF NATALIZUMAB VERSUS FINGOLIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SWEDEN
    Alexopoulos, S. T.
    Deniz, B.
    Walker, A. R.
    Arnold, R.
    Bates, D.
    VALUE IN HEALTH, 2012, 15 (04) : A145 - A145
  • [7] Oral fingolimod for relapsing-remitting multiple sclerosis
    Doggrell, Sheila A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1777 - 1781
  • [8] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Hanni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Ozgur
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
  • [9] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Cavit Boz
    Serkan Ozakbas
    Murat Terzi
    Rana Karabudak
    Serhan Sevim
    Recai Turkoglu
    Aysun Soysal
    Belgin Petek Balcı
    Hüsnü Efendi
    Ömer Faruk Turan
    Nur Yüceyar
    Mehmet Fatih Yetkin
    Serap Zengin Karahan
    Meltem Demirkıran
    Sibel Guler
    Kadriye Agan
    Nefati Kıylıoğlu
    Cavid Baba
    Asli Tuncer
    Mesrure Köseoğlu
    Neurological Sciences, 2023, 44 : 2121 - 2129
  • [10] The comparative effectiveness of fingolimod, natalizumab, and ocrelizumab in relapsing-remitting multiple sclerosis
    Boz, Cavit
    Ozakbas, Serkan
    Terzi, Murat
    Karabudak, Rana
    Sevim, Serhan
    Turkoglu, Recai
    Soysal, Aysun
    Balci, Belgin Petek
    Efendi, Husnu
    Turan, Omer Faruk
    Yuceyar, Nur
    Yetkin, Mehmet Fatih
    Karahan, Serap Zengin
    Demirkiran, Meltem
    Guler, Sibel
    Agan, Kadriye
    Kiylioglu, Nefati
    Baba, Cavid
    Tuncer, Asli
    Koseoglu, Mesrure
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 2121 - 2129
12345